Effects of CD14, TLR2, TLR4, LPB, and IL‐6 Gene Polymorphisms on Chlamydia pneumoniae Growth in Human Macrophages In Vitro

Chlamydia pneumoniae is an obligate intracellular gram‐negative bacterium, which causes respiratory infections in humans. It can infect various cell types, e.g. vascular endothelial cells, smooth muscle cells and monocyte‐derived macrophages in vitro. The susceptibility of macrophages from healthy individuals to C. pneumoniae infection is highly variable. In this study, we evaluated the effects of innate immunity genes CD14 −260 C>T, TLR2 Arg753Gln, TLR4 Asp299Gly, LBP Phe436Leu and IL6 −174 G>C polymorphisms on C. pneumoniae growth in human macrophages in vitro. The growth of C. pneumoniae was highest in CD14 −260 C>T TT genotype cells and the difference to CC and CT genotypes was statistically significant (P = 0.032 and 0.022 respectively). The G‐allele of the IL6 −174 G>C polymorphism had a positive influence on chlamydial growth; the difference was statistically significant only between CC and GC genotypes (P = 0.018). TLR2 Arg 753Gln, TLR4 Asp299Gly, LBP Phe436Leu polymorphisms showed no effect on chlamydial growth.

[1]  W. Göpel,et al.  159C>T CD14 genotype--functional effects on innate immune responses in term neonates. , 2008, Human immunology.

[2]  M. Leinonen,et al.  Susceptibility of Human Monocyte‐macrophages to Chlamydia pneumoniae Infection In Vitro is Highly Variable and Associated with levels of Soluble CD14 and C. pneumoniae IgA and Human HSP‐IgG Antibodies in Serum , 2008, Scandinavian journal of immunology.

[3]  S. Dower,et al.  The role of TLR activation in inflammation , 2008, The Journal of pathology.

[4]  Yan Yu,et al.  EFFECTS OF CD14-159 C/T POLYMORPHISM ON CD14 EXPRESSION AND THE BALANCE BETWEEN PROINFLAMMATORY AND ANTI-INFLAMMATORY CYTOKINES IN WHOLE BLOOD CULTURE , 2007, Shock.

[5]  Alexis Peralta,et al.  Toll-like receptors are key participants in innate immune responses. , 2007, Biological research.

[6]  N. Halama,et al.  Rapid genotyping of lipopolysaccharide-binding protein (LBP) C(1341)-->T (Leu(436)-->Phe) polymorphism by LightCycler real-time PCR. , 2006, Journal of immunological methods.

[7]  E. Porcellini,et al.  Interleukin‐6 gene polymorphism is an age‐dependent risk factor for myocardial infarction in men , 2005, International journal of immunogenetics.

[8]  J. Rupp,et al.  Critical Investigation of the CD14 Promoter Polymorphism: Lack of a Role for In Vitro Cytokine Response and Membrane CD14 Expression , 2005, Clinical Diagnostic Laboratory Immunology.

[9]  T. Vaughan,et al.  Chlamydia pneumoniae and Lung Cancer: Epidemiologic Evidence , 2005, Cancer Epidemiology Biomarkers & Prevention.

[10]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[11]  W. Solbach,et al.  CD14 promoter polymorphism −159C>T is associated with susceptibility to chronic Chlamydia pneumoniae infection in peripheral blood monocytes , 2004, Genes and Immunity.

[12]  H. Eng,et al.  A CD14 promoter polymorphism is associated with CD14 expression and Chlamydia-stimulated TNFα production , 2004, Genes and Immunity.

[13]  R. Schumann,et al.  Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor -2, -4, and -9 genes. , 2004, Journal of immunological methods.

[14]  B. Yoldaş,et al.  The Arg753Gln polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease , 2004, European Respiratory Journal.

[15]  P. Verpillat,et al.  Association of the Toll-Like Receptor 4 Gene Asp299Gly Polymorphism With Acute Coronary Events , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[16]  M. Hirai,et al.  CD14 promoter polymorphism is associated with acute myocardial infarction resulting from insignificant coronary artery stenosis , 2003, Heart.

[17]  H. Eng,et al.  Association of CD14 promoter gene polymorphism and Chlamydia pneumoniae infection. , 2003, The Journal of infectious diseases.

[18]  D. Kunz,et al.  Rapid and reliable genotyping for the Toll-like receptor 4 A896G polymorphism using fluorescence-labeled hybridization probes in a real-time polymerase chain reaction assay. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[19]  C. Erridge,et al.  Monocytes Heterozygous for the Asp299Gly and Thr399Ile Mutations in the Toll-like Receptor 4 Gene Show No Deficit in Lipopolysaccharide Signalling , 2003, The Journal of experimental medicine.

[20]  N. Mackman,et al.  Chlamydia pneumoniae Induces Tissue Factor Expression in Mouse Macrophages via Activation of Egr-1 and the MEK-ERK1/2 Pathway , 2003, Circulation research.

[21]  U. Reischl,et al.  Rapid and Standardized Detection of Chlamydia pneumoniae Using LightCycler Real-Time Fluorescence PCR , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[22]  G. Cooke,et al.  Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.

[23]  J. Pitha,et al.  Polymorphisms in the Lipopolysaccharide-Binding Protein and Bactericidal/Permeability-Increasing Protein in Patients with Myocardial Infarction , 2002, Clinical chemistry and laboratory medicine.

[24]  Marina A Dobrovolskaia,et al.  Toll receptors, CD14, and macrophage activation and deactivation by LPS. , 2002, Microbes and infection.

[25]  B. Tiran,et al.  Aspirin Inhibits Chlamydia pneumoniae–Induced Nuclear Factor-&kgr;B Activation, Cytokine Expression, and Bacterial Development in Human Endothelial Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Netea,et al.  Non‐LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll‐like receptor 2‐dependent pathways , 2002, European journal of immunology.

[27]  H. Karahashi,et al.  Chlamydial Heat Shock Protein 60 Activates Macrophages and Endothelial Cells Through Toll-Like Receptor 4 and MD2 in a MyD88-Dependent Pathway1 , 2002, The Journal of Immunology.

[28]  P. Godowski,et al.  Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines , 2002, The Journal of Immunology.

[29]  M. Leinonen,et al.  Evidence for infectious agents in cardiovascular disease and atherosclerosis. , 2002, The Lancet. Infectious diseases.

[30]  E. Hawe,et al.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. , 2001, European heart journal.

[31]  F. Oswald,et al.  Survival of Chlamydia pneumoniae-Infected Mono Mac 6 Cells Is Dependent on NF-κB Binding Activity , 2001, Infection and Immunity.

[32]  R. Rossaint,et al.  Lack of association between the –260 C→T promoter polymorphism of the endotoxin receptor CD14 gene and the CD14 density of unstimulated human monocytes and soluble CD14 plasma levels , 2001, Intensive Care Medicine.

[33]  K. Fassbender,et al.  Real-time PCR assay with fluorescent hybridization probes for rapid interleukin-6 promoter (-174G-->C) genotyping. , 2001, Clinical chemistry.

[34]  H. Wagner,et al.  Predominant Role of Toll-Like Receptor 2 Versus 4 in Chlamydia pneumoniae-Induced Activation of Dendritic Cells , 2001, The Journal of Immunology.

[35]  S. Liu,et al.  [Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease]. , 2001, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[36]  G. Rothe,et al.  Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: Gender-specific genetic predisposition to sepsis , 2001, Critical care medicine.

[37]  R. Rossaint,et al.  Real-time PCR assay with fluorescent hybridization probes for rapid genotyping of the CD14 promotor polymorphism. , 2000, Clinical chemistry.

[38]  J. Mira,et al.  A Novel Polymorphism in the Toll-Like Receptor 2 Gene and Its Potential Association with Staphylococcal Infection , 2000, Infection and Immunity.

[39]  HediGierens,et al.  Interleukin-6 Stimulates LDL Receptor Gene Expression via Activation of Sterol-Responsive and Sp1 Binding Elements , 2000 .

[40]  W. März,et al.  Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[41]  F. Green,et al.  Cooperative Influence of Genetic Polymorphisms on Interleukin 6 Transcriptional Regulation* , 2000, The Journal of Biological Chemistry.

[42]  D. Schwartz,et al.  TLR4 mutations are associated with endotoxin hyporesponsiveness in humans , 2000, Nature Genetics.

[43]  P. Libby,et al.  Cutting Edge: Heat Shock Protein (HSP) 60 Activates the Innate Immune Response: CD14 Is an Essential Receptor for HSP60 Activation of Mononuclear Cells1 , 2000, The Journal of Immunology.

[44]  S. Akira,et al.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. , 1999, Immunity.

[45]  G. Schmitz,et al.  C(-260)-->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. , 1999, Circulation.

[46]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[47]  C. Janeway,et al.  Innate Immunity: The Virtues of a Nonclonal System of Recognition , 1997, Cell.

[48]  D. Albanes,et al.  Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer , 1997, International journal of cancer.

[49]  M. Heinemann,et al.  Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line , 1996, Infection and immunity.

[50]  M. Leinonen,et al.  Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. , 1996, Microbial pathogenesis.

[51]  J. Ramirez,et al.  Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells , 1996, Infection and immunity.

[52]  L. Jackson,et al.  Chlamydia pneumoniae (TWAR) , 1995, Clinical microbiology reviews.

[53]  E. O’Brien,et al.  In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae , 1995, Journal of clinical microbiology.

[54]  P. Saikku,et al.  An epidemic of infections due to Chlamydia pneumoniae in military conscripts. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  P. Heinrich,et al.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense. , 1993, The Clinical investigator.

[56]  D. Hahn,et al.  Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. , 1991, JAMA.

[57]  P. Saikku,et al.  A NEW RESPIRATORY TRACT PATHOGEN: CHLAMYDIA PNEUMONIAE STRAIN TWAR , 1990, The Journal of infectious diseases.